Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma, Follicular × Tirzepatide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 2 Endometrial Neoplasms 2 Endometrial Hyperplasia 2 Weight Loss 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Hyperplasia 1 Breast Neoplasms 1

Interventions

Rituximab 122 Cyclophosphamide 104 Peripheral Blood Stem Cell Transplantation 49 fludarabine phosphate 47 Etoposide 43 Mycophenolic Acid 39 Radiotherapy 38 Filgrastim 38 Tacrolimus 34 Whole-Body Irradiation 33 Busulfan 29 Melphalan 27 Vincristine 26 Methotrexate 26 Cytarabine 26 Cyclosporine 26 Prednisone 25 sargramostim 24 Antilymphocyte Serum 24 Doxorubicin 22 Lenalidomide 21 obinutuzumab 19 Carmustine 18 Bortezomib 18 fludarabine 17 Dexamethasone 17 Bendamustine Hydrochloride 17 Methylprednisolone 16 ibritumomab tiuxetan 14 Cord Blood Stem Cell Transplantation 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06651177 2026-03-05

TAB

University of Cincinnati

Phase 2 Recruiting

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡